Buprenorphine Hydrochloride

CHEMBL2368861 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

504.1 g/mol

LogP

—

Phase

4

The hydrochloride salt of buprenorphine, used to treat opioid dependence and chronic pain. It is available in sublingual, buccal, transdermal, and injectable formulations. Its partial agonist activity at mu-opioid receptors provides pain relief and reduces withdrawal while limiting abuse potential.

분자량

504.1000 g/mol

TPSA

62.20 Å²

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Psychiatry Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Schizophrenia Generalized Anxiety Disorder Insomnia Obesity Major Depressive Disorder Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Cardiovascular Disease Prostate Cancer Colorectal Cancer

작용 기전

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5.Cl

InChI

InChI=1S/C29H41NO4.ClH/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28;/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3;1H/t20-,21-,24-,26+,27-,28+,29+;/m1./s1

Molecular Formula

C29H42ClNO4

HBD / HBA

3 / 5

회전 가능 결합

5

무거운 원자

35

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

The hydrochloride salt of buprenorphine, used to treat opioid dependence and chronic pain. It is available in sublingual, buccal, transdermal, and injectable formulations. Its partial agonist activity at mu-opioid receptors provides pain relief and reduces withdrawal while limiting abuse potential.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Buprenorphine Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2368861. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3033050. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Buprenorphine Hydrochloride PillFYI에서

구조

핵심 데이터

분자식: C29H42ClNO4
동의어: 5

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.